Cancer Care


A Phase II, Multicenter, Single-Arm Study of MPDL2380A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Principal Investigator (?)
Study Number
This multicenter, single-arm study will evaluate the efficacy and safety of MPDL 3280A in patients with PD-L1-positive locally advanced or metastatic non-small c ell lung cancer. Patients will receive MPDL3280A 1200 mg intravenously every 3 w eeks as long as patients are experiencing clinical benefit as assessed by the in vestigator, i.e., in the absence of unacceptable toxicity or symptomatic deterio ation attributed to disease progression. 
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)


View more details from

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.